Supplementary References
References
 Bonyhadi ML, Rabin L, Salimi S, Brown DA, Kosek J, McCune JM, Kaneshima H. HIV
induces thymus depletion in vivo. Nature. 1993 Jun 24;363(6431):728-732.
 Su L, Kaneshima H, Bonyhadi M, Salimi S, Kraft D, Rabin L, McCune JM. HIV-1induced thymocyte depletion is associated with indirect cytopathogenicity and infection
of progenitor cells in vivo. Immunity. 1995 Jan;2(1):25-36.
 Jamieson BD, Uittenbogaart CH, Schmid I, Zack JA. High viral burden and rapid CD4+
cell depletion in human immunodeficiency virus type 1-infected SCID-hu mice suggest
direct viral killing of thymocytes in vivo. Journal of virology. 1997 Nov;71(11):82458253.
 Douek DC, Betts MR, Hill BJ, Little SJ, Lempicki R, Metcalf JA, Casazza J, Yoder C,
Adelsberger JW, Stevens RA, Baseler MW, Keiser P, Richman DD, Davey RT, Koup
RA. Evidence for increased T cell turnover and decreased thymic output in HIV
infection. J Immunol. 2001 Dec 1;167(11):6663-6668.
 Hazenberg MD, Verschuren MC, Hamann D, Miedema F, van Dongen JJ. T cell receptor
excision circles as markers for recent thymic emigrants: basic aspects, technical
approach, and guidelines for interpretation. J Mol Med 2001 Nov; 79(11): 631-640.
 Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell Jt, Bixby D, Savona MR, et al. HIV1 infects multipotent progenitor cells causing cell death and establishing latent cellular
reservoirs. Nat Med Apr; 16(4): 446-451.
 Samuelsson A, Brostrom C, van Dijk N, Sonnerborg A, Chiodi F. Apoptosis of CD4+ and
CD19+ cells during human immunodeficiency virus type 1 infection--correlation with
clinical progression, viral load, and loss of humoral immunity. Virology. 1997 Nov
24;238(2):180-188.
 Nie Z, Bren GD, Rizza SA, Badley AD. HIV Protease Cleavage of Procaspase 8 is
Necessary for Death of HIV-Infected Cells. Open Virol J 2008; 2: 1-7.
 Muro-Cacho CA, Pantaleo G, Fauci AS. Analysis of apoptosis in lymph nodes of HIVinfected persons. Intensity of apoptosis correlates with the general state of activation of
the lymphoid tissue and not with stage of disease or viral burden. J Immunol 1995 May
15; 154(10): 5555-5566.
 Chen JJ, Huang JC, Shirtliff M, Briscoe E, Ali S, Cesani F, Paar D, Cloyd MW. CD4
lymphocytes in the blood of HIV(+) individuals migrate rapidly to lymph nodes and bone
marrow: support for homing theory of CD4 cell depletion. J Leukoc Biol. 2002
Aug;72(2):271-278.
 Ji J, Cloyd MW. HIV-1 binding to CD4 on CD4+CD25+ regulatory T cells enhances their
suppressive function and induces them to home to, and accumulate in, peripheral and
mucosal lymphoid tissues: an additional mechanism of immunosuppression. Int
Immunol. 2009 Mar;21(3):283-294.
 Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, et al. Chimpanzee
reservoirs of pandemic and nonpandemic HIV-1. Science 2006 Jul 28; 313(5786): 523526.
 Paiardini M, Cervasi B, Sumpter B, McClure HM, Sodora DL, Magnani M, Staprans SI,
Piedimonte G, Silvestri G. Perturbations of cell cycle control in T cells contribute to the
different outcomes of simian immunodeficiency virus infection in rhesus macaques and
sooty mangabeys. Journal of virology. 2006 Jan;80(2):634-642.
 Keele BF, Jones JH, Terio KA, Estes JD, Rudicell RS, Wilson ML, Li Y, Learn GH,
Beasley TM, Schumacher-Stankey J, Wroblewski E, Mosser A, Raphael J, Kamenya S,
Lonsdorf EV, Travis DA, Mlengeya T, Kinsel MJ, Else JG, Silvestri G, Goodall J, Sharp
PM, Shaw GM, Pusey AE, Hahn BH. Increased mortality and AIDS-like
immunopathology in wild chimpanzees infected with SIVcpz. Nature. 2009 Jul
23;460(7254):515-519.
 Hurtrel B, Petit F, Arnoult D, Muller-Trutwin M, Silvestri G, Estaquier J. Apoptosis in SIV
infection. Cell Death Differ. 2005 Aug;12 Suppl 1:979-990.
 Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P,
Butor C, Silvestri G, Giavedoni LD, Lebon P, Barre-Sinoussi F, Benecke A, MullerTrutwin MC. Nonpathogenic SIV infection of African green monkeys induces a strong
but rapidly controlled type I IFN response. J Clin Invest. 2009 Dec;119(12):3544-3555.
 Liegler TJ, Yonemoto W, Elbeik T, Vittinghoff E, Buchbinder SP, Greene WC.
Diminished spontaneous apoptosis in lymphocytes from human immunodeficiency virusinfected long-term nonprogressors. The Journal of infectious diseases. 1998
Sep;178(3):669-679.
 Franceschi C, Franceschini MG, Boschini A, Trenti T, Nuzzo C, Castellani G, et al.
Phenotypic characteristics and tendency to apoptosis of peripheral blood mononuclear
cells from HIV+ long term non progressors. Cell Death Differ 1997 Dec; 4(8): 815-823.
 Bahbouhi B, Landay A, Al-Harthi L. Dynamics of cytokine expression in HIV
productively infected primary CD4+ T cells. Blood. 2004 Jun 15;103(12):4581-4587.
 Estaquier J, Idziorek T, Zou W, Emilie D, Farber CM, Bourez JM, Ameisen JC. T helper
type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on
activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from
human immunodeficiency virus-infected persons. The Journal of experimental medicine.
1995 Dec 1;182(6):1759-1767.
 Prendergast A, Prado JG, Kang YH, Chen F, Riddell LA, Luzzi G, Goulder P, Klenerman
P. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and
gradual decline in regulatory T cells. AIDS (London, England). Feb 20;24(4):491-502.
 El Hed A, Khaitan A, Kozhaya L, Manel N, Daskalakis D, Borkowsky W, Valentine F,
Littman
DR,
Unutmaz
D. Susceptibility of
human
Th17
cells
to
human
immunodeficiency virus and their perturbation during infection. The Journal of infectious
diseases. Mar 15;201(6):843-854.
 Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA, Herzenberg LA. Fas antigen
stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency
virus-infected individuals. The Journal of experimental medicine. 1995 Jun
1;181(6):2029-2036.
 McCloskey TW, Oyaizu N, Kaplan M, Pahwa S. Expression of the Fas antigen in patients
infected with human immunodeficiency virus. Cytometry. 1995 Jun 15;22(2):111-114.
 Aries SP, Schaaf B, Muller C, Dennin RH, Dalhoff K. Fas (CD95) expression on CD4+ T
cells from HIV-infected patients increases with disease progression. J Mol Med. 1995
Dec;73(12):591-593.
 Gehri R, Hahn S, Rothen M, Steuerwald M, Nuesch R, Erb P. The Fas receptor in HIV
infection: expression on peripheral blood lymphocytes and role in the depletion of T
cells. AIDS (London, England). 1996 Jan;10(1):9-16.
 Sloand EM, Young NS, Kumar P, Weichold FF, Sato T, Maciejewski JP. Role of Fas
ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency
syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus
replication. Blood. 1997 Feb 15;89(4):1357-1363.
 Jiang JD, Schlesinger M, Sacks H, Mildvan D, Roboz JP, Bekesi JG. Concentrations of
soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+,
and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status. J Clin
Immunol 1997 Mar; 17(2): 185-192.
 Dockrell DH, Badley AD, Villacian JS, Heppelmann CJ, Algeciras A, Ziesmer S, Yagita
H, Lynch DH, Roche PC, Leibson PJ, Paya CV. The expression of Fas Ligand by
macrophages and its upregulation by human immunodeficiency virus infection. J Clin
Invest. 1998 Jun 1;101(11):2394-2405.
 Kobayashi N, Hamamoto Y, Yamamoto N, Ishii A, Yonehara M, Yonehara S. Anti-Fas
monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells
without augmenting viral replication. Proc Natl Acad Sci U S A 1990 Dec; 87(24): 96209624.
 Badley AD, Dockrell D, Simpson M, Schut R, Lynch DH, Leibson P, et al. Macrophagedependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated
by FasL and tumor necrosis factor. J Exp Med 1997 Jan 6; 185(1): 55-64.
 Medrano FJ, Leal M, Arienti D, Rey C, Zagliani A, Torres Y, Sanchez-Quijano A, Lissen
E, Clerici M. Tumor necrosis factor beta and soluble APO-1/Fas independently predict
progression to AIDS in HIV-seropositive patients. AIDS research and human
retroviruses. 1998 Jul 1;14(10):835-843.
 Moretti S, Marcellini S, Boschini A, Famularo G, Santini G, Alesse E, Steinberg SM,
Cifone MG, Kroemer G, De Simone C. Apoptosis and apoptosis-associated perturbations
of peripheral blood lymphocytes during HIV infection: comparison between AIDS
patients and asymptomatic long-term non-progressors. Clin Exp Immunol. 2000
Dec;122(3):364-373.
 Wong GH, Krowka JF, Stites DP, Goeddel DV. In vitro anti-human immunodeficiency
virus activities of tumor necrosis factor-alpha and interferon-gamma. J Immunol. 1988
Jan 1;140(1):120-124.
 Kaplan LD, Abrams DI, Sherwin SA, Kahn J, Volberding PA. A phase I/II study of
recombinant tumor necrosis factor and recombinant interferon gamma in patients with
AIDS-related complex. Biotechnol Ther. 1989;1(3):229-236.
 Cummins N, Badley A. The TRAIL to Viral Pathogenesis: The Good, the Bad and the
Ugly. Curr Mol Med 2009 Jun; 9(4): 495-505.
 Herbeuval JP, Grivel JC, Boasso A, Hardy AW, Chougnet C, Dolan MJ, et al. CD4+ T-cell
death induced by infectious and noninfectious HIV-1: role of type 1 interferondependent, TRAIL/DR5-mediated apoptosis. Blood 2005 Nov 15; 106(10): 3524-3531.
 Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, et al. Plasmacytoid
dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic
patients. Blood 2009 Oct 29; 114(18): 3854-3863.
 Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for
cancer therapy: the promises and the challenges. Rev Recent Clin Trials. 2009
Jan;4(1):34-41.
 Cadogan M, Dalgleish AG. Pathogenesis of HIV: non-specific immune hyperactivity and
its implications for vaccines. Clin Med. 2008 Jun;8(3):267-271.
 Brenner D, Krammer PH, Arnold R. Concepts of activated T cell death. Crit Rev Oncol
Hematol. 2008 Apr;66(1):52-64.
 Holm GH, Gabuzda D. Distinct mechanisms of CD4+ and CD8+ T-cell activation and
bystander apoptosis induced by human immunodeficiency virus type 1 virions. Journal of
virology. 2005 May;79(10):6299-6311.
 Marchetti G, Bellistri GM, Borghi E, Tincati C, Ferramosca S, La Francesca M, Morace G,
Gori A, Monforte AD. Microbial translocation is associated with sustained failure in
CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active
antiretroviral therapy. AIDS (London, England). 2008 Oct 1;22(15):2035-2038.
 Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. Plasma levels of
bacterial DNA correlate with immune activation and the magnitude of immune
restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009 Apr 15;
199(8): 1177-1185.
 Andrieu JM, Lu W. Long-term clinical, immunologic and virologic impact of
glucocorticoids on the chronic phase of HIV infection. BMC Med. 2004 May 5;2:17.
 Calabrese LH, Lederman MM, Spritzler J, Coombs RW, Fox L, Schock B, Yen-Lieberman
B, Johnson R, Mildvan D, Parekh N. Placebo-controlled trial of cyclosporin-A in HIV-1
disease: implications for solid organ transplantation. Journal of acquired immune
deficiency syndromes. 2002 Apr 1;29(4):356-362.
 Lederman MM, Smeaton L, Smith KY, Rodriguez B, Pu M, Wang H, Sevin A, Tebas P,
Sieg SF, Medvik K, Margolis DM, Pollard R, Ertl HC, Valdez H. Cyclosporin A provides
no sustained immunologic benefit to persons with chronic HIV-1 infection starting
suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS
Clinical Trials Group A5138. The Journal of infectious diseases. 2006 Dec
15;194(12):1677-1685.
 Kvale D, Ormaasen V, Kran AM, Johansson CC, Aukrust P, Aandahl EM, Froland SS,
Tasken K. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV
patients on combination antiretroviral treatment. AIDS (London, England). 2006 Apr
4;20(6):813-820.
 Kaur R, Bedimo R, Kvanli MB, Turner D, Shaw L, Margolis D. A placebo-controlled pilot
study of intensification of antiretroviral therapy with mycophenolate mofetil. AIDS Res
Ther. 2006;3:16.
 Engchanil C, Kosalaraksa P, Lumbiganon P, Lulitanond V, Pongjunyakul P, Thuennadee
R, Tungsawad S, Suwan-apichon O. Therapeutic potential of chloroquine added to
zidovudine plus didanosine for HIV-1 infected children. J Med Assoc Thai. 2006
Aug;89(8):1229-1236.
 Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, Finkel TH.
Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for
activation-induced apoptosis. The Journal of experimental medicine. 1992 Oct
1;176(4):1099-1106.
 Schwartz O, Alizon M, Heard JM, Danos O. Impairment of T cell receptor-dependent
stimulation in CD4+ lymphocytes after contact with membrane-bound HIV-1 envelope
glycoprotein. Virology. 1994 Jan;198(1):360-365.
 Laurent-Crawford AG, Krust B, Riviere Y, Desgranges C, Muller S, Kieny MP, Dauguet
C, Hovanessian AG. Membrane expression of HIV envelope glycoproteins triggers
apoptosis in CD4 cells. AIDS research and human retroviruses. 1993 Aug;9(8):761-773.
 Amendola A, Lombardi G, Oliverio S, Colizzi V, Piacentini M. HIV-1 gp120-dependent
induction of apoptosis in antigen-specific human T cell clones is characterized by 'tissue'
transglutaminase expression and prevented by cyclosporin A. FEBS Lett. 1994 Feb
21;339(3):258-264.
 Laurent-Crawford AG, Coccia E, Krust B, Hovanessian AG. Membrane-expressed HIV
envelope glycoprotein heterodimer is a powerful inducer of cell death in uninfected
CD4+ target cells. Res Virol. 1995 Jan-Feb;146(1):5-17.
 Foster S, Beverley P, Aspinall R. gp120-induced programmed cell death in recently
activated T cells without subsequent ligation of the T cell receptor. Eur J Immunol. 1995
Jun;25(6):1778-1782.
 Jekle A, Keppler OT, De Clercq E, Schols D, Weinstein M, Goldsmith MA. In vivo
evolution of human immunodeficiency virus type 1 toward increased pathogenicity
through CXCR4-mediated killing of uninfected CD4 T cells. J Virol 2003 May; 77(10):
5846-5854.
 Perfettini JL, Castedo M, Roumier T, Andreau K, Nardacci R, Piacentini M, et al.
Mechanisms of apoptosis induction by the HIV-1 envelope. Cell Death Differ 2005 Aug;
12 Suppl 1: 916-923.
 Uchiyama J, Kishi S, Yagita H, Matsuzaki S, Koga Y. Fas ligand-mediated depletion of
CD4 and CD8 lymphocytes by monomeric HIV-1-gp120. Arch Virol. 1997;142(9):17711785.
 Muller WE, Pergande G, Ushijima H, Schleger C, Kelve M, Perovic S. Neurotoxicity in rat
cortical cells caused by N-methyl-D-aspartate (NMDA) and gp120 of HIV-1: induction
and pharmacological intervention. Prog Mol Subcell Biol. 1996;16:44-57.
 Huang MB, Hunter M, Bond VC. Effect of extracellular human immunodeficiency virus
type 1 glycoprotein 120 on primary human vascular endothelial cell cultures. AIDS
research and human retroviruses. 1999 Sep 20;15(14):1265-1277.
 Twu C, Liu NQ, Popik W, Bukrinsky M, Sayre J, Roberts J, Rania S, Bramhandam V,
Roos KP, MacLellan WR, Fiala M. Cardiomyocytes undergo apoptosis in human
immunodeficiency virus cardiomyopathy through mitochondrion- and death receptorcontrolled pathways. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14386-14391.
 Kapasi AA, Patel G, Franki N, Singhal PC. HIV-1 gp120-induced tubular epithelial cell
apoptosis is mediated through p38-MAPK phosphorylation. Mol Med. 2002
Nov;8(11):676-685.
 Munshi N, Balasubramanian A, Koziel M, Ganju RK, Groopman JE. Hepatitis C and
human immunodeficiency virus envelope proteins cooperatively induce hepatocytic
apoptosis via an innocent bystander mechanism. The Journal of infectious diseases. 2003
Oct 15;188(8):1192-1204.
 Vlahakis
SR, Villasis-Keever A, Gomez
TS, Bren GD, Paya
CV. Human
immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. The
Journal of infectious diseases. 2003 Nov 15;188(10):1455-1460.
 Acheampong EA, Parveen Z, Muthoga LW, Wasmuth-Peroud V, Kalayeh M, Bashir A,
Diecidue R, Mukhtar
M,
Pomerantz
RJ. Molecular interactions
of human
immunodeficiency virus type 1 with primary human oral keratinocytes. Journal of
virology. 2005 Jul;79(13):8440-8453.
 Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1
secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem
Biophys Res Commun. 2005 Aug 12;333(4):1107-1115.
 Endo M, Inatsu A, Hashimoto K, Takamune N, Shoji S, Misumi S. Human
immunodeficiency virus-induced apoptosis of human breast cancer cells via CXCR4 is
mediated by the viral envelope protein but does not require CD4. Curr HIV Res. 2008
Jan;6(1):34-42.
 Gibellini D, De Crignis E, Ponti C, Cimatti L, Borderi M, Tschon M, Giardino R, Re MC.
HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha
activation. J Med Virol. 2008 Sep;80(9):1507-1514.
 Singh S, Bond VC, Powell M, Singh UP, Bumpers HL, Grizzle WE, Lillard JW, Jr.
CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer
cells and inhibit tumor growth. Mol Cancer Ther. 2009 Jan;8(1):178-184.
 Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from
cells via a leaderless secretory pathway and binds to extracellular matrix-associated
heparan sulfate proteoglycans through its basic region. AIDS (London, England). 1997
Oct;11(12):1421-1431.
 Sahaf B, Atkuri K, Heydari K, Malipatlolla M, Rappaport J, Regulier E, Herzenberg LA,
Herzenberg LA. Culturing of human peripheral blood cells reveals unsuspected
lymphocyte responses relevant to HIV disease. Proc Natl Acad Sci U S A. 2008 Apr
1;105(13):5111-5116.
 Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M, Monne M, et al. The human
immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat
T-cell lines and primary peripheral blood mononuclear cells. Blood 1995 Nov 15; 86(10):
3823-3834.
 Zhang M, Li X, Pang X, Ding L, Wood O, Clouse K, Hewlett I, Dayton AI. Identification
of a potential HIV-induced source of bystander-mediated apoptosis in T cells:
upregulation of trail in primary human macrophages by HIV-1 tat. J Biomed Sci. 2001
May-Jun;8(3):290-296.
 Collins KL. This bud's for Vpu. Cell Host Microbe. 2009 Mar 19;5(3):217-219.
 Joseph AM, Kumar M, Mitra D. Nef: "necessary and enforcing factor" in HIV infection.
Curr HIV Res. 2005 Jan;3(1):87-94.
 Okada H, Takei R, Tashiro M. HIV-1 Nef protein-induced apoptotic cytolysis of a broad
spectrum of uninfected human blood cells independently of CD95(Fas). FEBS Lett. 1997
Sep 15;414(3):603-606.
 Xu XN, Laffert B, Screaton GR, Kraft M, Wolf D, Kolanus W, Mongkolsapay J,
McMichael AJ, Baur AS. Induction of Fas ligand expression by HIV involves the
interaction of Nef with the T cell receptor zeta chain. The Journal of experimental
medicine. 1999 May 3;189(9):1489-1496.
 Andersen JL, Le Rouzic E, Planelles V. HIV-1 Vpr: mechanisms of G2 arrest and
apoptosis. Exp Mol Pathol. 2008 Aug;85(1):2-10.
 Chang LJ, Chen CH, Urlacher V, Lee TZ. Differential apoptosis effects of primate
lentiviral Vpr and Vpx in mammalian cells. J Biomed Sci. 2000 Jul-Aug;7(4):322-333.
 Conti L, Matarrese P, Varano B, Gauzzi MC, Sato A, Malorni W, Belardelli F, Gessani S.
Dual role of the HIV-1 vpr protein in the modulation of the apoptotic response of T cells.
J Immunol. 2000 Sep 15;165(6):3293-3300.
 Jian H, Zhao LJ. Pro-apoptotic activity of HIV-1 auxiliary regulatory protein Vpr is
subtype-dependent and potently enhanced by nonconservative changes of the leucine
residue at position 64. J Biol Chem 2003 Nov 7; 278(45): 44326-44330.
 Andersen JL, DeHart JL, Zimmerman ES, Ardon O, Kim B, Jacquot G, et al. HIV-1 Vprinduced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog
2006 Dec; 2(12): e127.
 Shostak LD, Ludlow J, Fisk J, Pursell S, Rimel BJ, Nguyen D, Rosenblatt JD, Planelles V.
Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1
vpr. Exp Cell Res. 1999 Aug 25;251(1):156-165.
 Muthumani K, Hwang DS, Desai BM, Zhang D, Dayes N, Green DR, Weiner DB. HIV-1
Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear
cells. J Biol Chem. 2002 Oct 4;277(40):37820-37831.
 Arunagiri C, Macreadie I, Hewish D, Azad A. A C-terminal domain of HIV-1 accessory
protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human
CD4+ lymphocytes. Apoptosis. 1997;2(1):69-76.
 Yasuda J, Miyao T, Kamata M, Aida Y, Iwakura Y. T cell apoptosis causes peripheral T
cell depletion in mice transgenic for the HIV-1 vpr gene. Virology 2001 Jul 5; 285(2):
181-192.
 Muthumani K, Lambert VM, Sardesai NY, Kim JJ, Heller R, Weiner DB, et al. Analysis of
the potential for HIV-1 Vpr as an anti-cancer agent. Curr HIV Res 2009 Mar; 7(2): 144152.
 Nie Z, Phenix BN, Lum JJ, Alam A, Lynch DH, Beckett B, et al. HIV-1 protease processes
procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and
nuclear fragmentation. Cell Death Differ 2002 Nov; 9(11): 1172-1184.
 Dezube BJ, Pardee AB, Chapman B, Beckett LA, Korvick JA, Novick WJ, Chiurco J,
Kasdan P, Ahlers CM, Ecto LT, et al. Pentoxifylline decreases tumor necrosis factor
expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials
Group. Journal of acquired immune deficiency syndromes. 1993 Jul;6(7):787-794.
 Luke DR, McCreedy BJ, Sarnoski TP, Bookout JB, Johnston AM, Lell JE, Wiggan EB,
Bell N, Limjuco RA, Guthrie KI, et al. Phase I/II study of pentoxifylline with zidovudine
on HIV-1 growth in AIDS patients. International journal of clinical pharmacology,
therapy, and toxicology. 1993 Jul;31(7):343-350.
 Dezube BJ, Lederman MM, Spritzler JG, Chapman B, Korvick JA, Flexner C, Dando S,
Mattiacci MR, Ahlers CM, Zhang L, et al. High-dose pentoxifylline in patients with
AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and
Infectious Diseases AIDS Clinical Trials Group. The Journal of infectious diseases. 1995
Jun;171(6):1628-1632.
 Kruse A, Rieneck K, Kappel M, Orholm M, Bruunsgaard H, Ullum H, Skinhoj P, Pedersen
BK. Pentoxifylline therapy in HIV seropositive subjects with elevated TNF.
Immunopharmacology. 1995 Nov;31(1):85-91.
 Clerici M, Piconi S, Balotta C, Trabattoni D, Capetti A, Fusi ML, Ruzzante S, Longhi R,
Colombo MC, Moroni M, Milazzo F. Pentoxifylline improves cell-mediated immunity
and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic
HIV-seropositive persons. The Journal of infectious diseases. 1997 May;175(5):12101215.
 Heijligenberg R, Romijn JA, Ackermans M, Endert E, Timmer JG, Sauerwein HP. The
maximal tolerable intravenous dosage of pentoxifylline in AIDS patients does not inhibit
lipopolysaccharide-stimulated tumor necrosis factor alpha production. AIDS research and
human retroviruses. 1998 Mar 1;14(4):299-303.
 Wanchu A, Bhatnagar A, Kumar B, Bambery P, Singh S. Reduced apoptosis by
pentoxiphylline among patients with HIV infection. International immunopharmacology.
2003 Mar;3(3):359-364.
 Ockenga J, Rohde F, Suttmann U, Herbarth L, Ballmaier M, Schedel I. Ketotifen in HIVinfected patients: effects on body weight and release of TNF-alpha. European journal of
clinical pharmacology. 1996;50(3):167-170.
 Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A,
Calva JJ, Ruiz-Palacios GM. Effects of thalidomide on HIV-associated wasting
syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS (London,
England). 1996 Nov;10(13):1501-1507.
 Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff
M, Wu AW, MacPhail LA, Vasquez GJ, Wohl DA. Thalidomide for the treatment of oral
aphthous ulcers in patients with human immunodeficiency virus infection. National
Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. The New
England journal of medicine. 1997 May 22;336(21):1487-1493.
 Marriott JB, Cookson S, Carlin E, Youle M, Hawkins DA, Nelson M, Pearson M, Vaughan
AN, Gazzard B, Dalgleish AG. A double-blind placebo-controlled phase II trial of
thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on
activation markers and cytokines. AIDS research and human retroviruses. 1997 Dec
10;13(18):1625-1631.
 Haslett PA, Klausner JD, Makonkawkeyoon S, Moreira A, Metatratip P, Boyle B,
Kunachiwa W, Maneekarn N, Vongchan P, Corral LG, Elbeik T, Shen Z, Kaplan G.
Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected
patients. AIDS research and human retroviruses. 1999 Sep 1;15(13):1169-1179.
 Sha BE, Valdez H, Gelman RS, Landay AL, Agosti J, Mitsuyasu R, Pollard RB, Mildvan
D, Namkung A, Ogata-Arakaki DM, Fox L, Estep S, Erice A, Kilgo P, Walker RE,
Bancroft L, Lederman MM. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis
factor alpha, and markers of immune activation in HIV-infected subjects receiving
interleukin 2. AIDS research and human retroviruses. 2002 Jun 10;18(9):661-665.
 Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M, Ducar C, Millard M,
Mayanja-Kizza H, Whalen C, Okwera A. A study of the safety, immunology, virology,
and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS
(London, England). 2004 Jan 23;18(2):257-264.
 Zhang S, Carper MJ, Lei X, Cade WT, Yarasheski KE, Ramanadham S. Protease inhibitors
used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway
and compromise insulin secretion. Am J Physiol Endocrinol Metab. 2009
Apr;296(4):E925-935.
 Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S. Cross-linking of
CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing
interferon-gamma and tumor necrosis factor- alpha secretion. Blood. 1994;84(8):26222631.
 Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM,
Krammer PH. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and
gp120. Nature. 1995;375(6531):497-500.
 Bartz SR, Emerman M. Human immunodeficiency virus type 1 Tat induces apoptosis and
increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. J Virol.
1999;73(3):1956-1963.
 Zauli G, Gibellini D, Secchiero P, Dutartre H, Olive D, Capitani S, Collette Y. Human
immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to
apoptosis via functional upregulation of the CD95/CD95 ligand pathway. Blood.
1999;93(3):1000-1010.
 Wolf D, Witte V, Laffert B, Blume K, Stromer E, Trapp S, d'Aloja P, Schurmann A, Baur
AS. HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Badphosphorylation to induce anti-apoptotic signals. Nat Med. 2001;7(11):1217-1224.
 Greenway AL, McPhee DA, Allen K, Johnstone R, Holloway G, Mills J, Azad A,
Sankovich S, Lambert P. Human immunodeficiency virus type 1 Nef binds to tumor
suppressor p53 and protects cells against p53-mediated apoptosis. J Virol.
2002;76(6):2692-2702.
 Ayyavoo V, Mahboubi A, Mahalingam S, Ramalingam R, Kudchodkar S, Williams WV,
Green DR, Weiner DB. HIV-1 Vpr suppresses immune activation and apoptosis through
regulation of nuclear factor kappa B. Nat Med. 1997;3(10):1117-1123.
 Strack PR, Frey MW, Rizzo CJ, Cordova B, George HJ, Meade R, Ho SP, Corman J,
Tritch R, Korant BD. Apoptosis mediated by HIV protease is preceded by cleavage of
Bcl-2. Proc Natl Acad Sci U S A. 1996;93(18):9571-9576.